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Abstract
Background
In order to assess the level of transmitted and/or pre-treatment antiretroviral drug resistance
to HIV-1, the World Health Organization (WHO) recommends that regular surveys are con-
ducted. This study’s objective was to assess the frequency of HIV-1 antiretroviral drug resis-
tance in patients initiating antiretroviral treatment (ART) in the public sector throughout
South Africa.
Methods
A prospective cross-sectional survey was conducted using probability proportional to size
sampling. This method ensured that samples from each province were proportionally col-
lected, based on the number of patients receiving ART in each region. Samples were col-
lected between March 2013 and October 2014. Pol sequences were obtained using RT-
PCR and Sanger sequencing and submitted to the Stanford Calibrated Population Resis-
tance tool v6.0.
Results
A total of 277 sequences were available for analysis. Most participants were female (58.8%)
and the median age was 34 years (IQR: 29–42). The median baseline CD4-count was 149
cells/mm3 (IQR: 62–249) and, based on self-reporting, participants had been diagnosed as
HIV-positive approximately 44 days prior to sample collection (IQR: 23–179). Subtyping
revealed that 98.2% were infected with HIV-1 subtype C. Overall, 25 out of 277 patients pre-
sented with1 surveillance drug resistance mutation (SDRM, 9.0%, 95% CI: 6.1–13.0%).
Non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations were the most numerous
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mutations detected (n = 23). Only two patients presented with a protease inhibitor (PI) muta-
tion. In four patients4 SDRMs were detected, which might indicate that these patients
were not truly ART-naïve or were infected with a multi-resistant virus.
Conclusions
These results show that the level of antiretroviral drug resistance in ART-naïve South Afri-
cans has reached moderate levels, as per the WHO classification. Therefore, regular sur-
veys of pre-treatment drug resistance levels in all regions of South Africa is highly
recommended to monitor the changing levels of pre-treatment antiretroviral drug resistance.
Introduction
South Africa has the largest antiretroviral treatment (ART) program in the world with an esti-
mated cumulative number of individuals on treatment of 3.1 million[1]. Transmitted HIV drug
resistance (TDR) implies that newly-infected individuals are infected with a drug-resistant
virus. With increased treatment coverage, TDR is expected to increase, especially in settings
relying on clinical and CD4 monitoring to detect treatment failure, whereas the early detection
of failure through viral load monitoring coupled with a timely switch to second-line therapy
may protect against an increase in TDR [2]. The presence of pre-treatment resistance can lead
to an increased risk of virological failure and modelling predicts that increased TDR would have
a significant impact on future HIV mortality [3–5]. Onward transmission of antiretroviral drug
resistance from patients failing first-line therapy may therefore compromise South Africa’s suc-
cess toward reaching the last 90% of the UNAIDS 90-90-90 target by 2020, which is achieving
90% viral suppression in patients on antiretroviral combination therapy [6].
The definition of TDR can theoretically only be applied to recently-infected individuals as
transmitted mutations may revert back to wild type, or only be present at levels below the sen-
sitivity of standard genotyping assays [7]. Since it is very challenging to identify recently-
infected individuals, both recently- and chronically-infected individuals who start ART are
often included in surveys.
The WHO has classified levels of TDR into three categories: low (<5%), moderate (5–15%)
and high levels (>15%) [8]. The 2012 WHO HIV drug resistance report, which included sur-
vey data from 2004 to 2010, stated that most surveys (72.2%, 52/72) detected low prevalence
(<5%) of TDR to all drug classes. However, 20 surveys showed a moderate level of TDR (5–
15%) to one or more antiretroviral drug classes. Moderate levels of TDR were most commonly
observed against the NNRTI drug class. Overall, 13 out of 20 surveys (65%) showing a moder-
ate prevalence of TDR to any drug class were conducted in the African region, particularly east
Africa [9]. A more recent meta-analysis suggested that the median overall level of TDR in sub-
Saharan Africa was limited to 2.9% with a yearly 1.09-fold (95% CI: 1.05–1.14) increase in
odds of TDR since national ARV scale-up, attributable to an increase in non-nucleoside
reverse transcriptase inhibitor (NNRTI) resistance [10]. Earlier mathematical models have
suggested that the 5% threshold for TDR would only be breached 10 years after large-scale
ART roll-out, or when at least 30% of HIV-infected patients are on ART [8]. As 2014 marked a
decade of large-scale ART roll-out in South Africa and more than 80% of the HIV-infected
South African individuals in need of ART, based on a CD4-count of 350 cells/mm3 were on
treatment by the end of 2012, an increasing level of transmitted and/or pre-treatment drug
resistance in the South African population can be expected.
Pre-Treatment HIV-1 Drug Resistance in South Africa
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Since 2002, various surveys addressing the level of transmitted or pre-treatment drug resis-
tance have been conducted in South Africa. For ease of reference no distinction was made
between studies that targeted only recently-infected individuals versus any patient prior to
ART initiation. Gauteng and KwaZulu-Natal were the most surveyed regions. The studies con-
ducted in Gauteng, Free State and Mpumalanga consistently detected a low prevalence of TDR
[11–14]. The detected prevalence in KwaZulu-Natal changed from low levels in 2005 and 2007
to moderate levels of TDR in 2008 and 2009 [13]. These moderate levels were confirmed by
one study [15], but not by two additional studies from the region [16, 17]. A recent temporal
analysis of transmitted drug resistance in KwaZulu-Natal showed an increase between 2010
and 2012 [18]. A single study from Limpopo also detected moderate levels of TDR [19].
Despite the prevalence of TDR remaining low in the Western Cape, the latest data suggest that
this prevalence is on the rise [20–22].
This study therefore aimed to conduct the very first national pre-treatment drug resistance
survey to assess the current situation in the whole of South Africa.
Materials and Methods
Survey design
In estimating the proportion of ART naïve patients that had transmitted or pre-treatment
resistance at a national level, we had two considerations: the size of the sample and how to
select samples to represent South Africa. For the size of the sample, with 277 sequences we
had sufficient statistical power to detect a 10% prevalence with a margin of error of +/- 3.5%,
which we deemed sufficient to estimate this proportion. We selected the samples from the
provinces proportional to the HIV population of the sample in order to achieve a proportional
distribution of ART naïve individuals using probability proportional to size sampling (PPSS).
South Africa has 9 provinces and 52 districts. Only tier two facilities with at least 500 patients
in ART care were considered, to ensure adequate sampling options. The number of patients in
care per facility was obtained from the South African District Health Information System. Any
patient initiating ART or attending a pre-treatment follow-up visit, without prior ART expo-
sure, who was at least 18 years of age and had signed informed consent, was eligible to be
included in the study. Due to the lack of research staff at the health care facilities, a non-ran-
dom sample of patients was used for this survey.
Data and sample collection
Health care professionals at sentinel sites informed eligible patients of the HIV antiretroviral
drug resistance survey. After obtaining written informed consent, a study questionnaire was
completed. The study questionnaire included questions regarding basic demographics, ART
history and CD4 counts. Subsequently, whole blood was collected in EDTA-vacutainers. The
samples were then sent to one of three participating HIV genotyping laboratories: Tygerberg
Hospital, Stellenbosch processed samples collected in the Western Cape; Universitas, Bloem-
fontein, processed samples collected in the Free State and the laboratory at Charlotte Maxeke
Johannesburg Academic Hospital, Johannesburg processed the samples collected in the
remaining provinces. To ensure sample integrity, it was advised that the specimens should
reach the relevant laboratories within 72 hours after sample collection. Upon receipt, samples
were centrifuged and plasma was stored at -80˚C until processing. Each laboratory used their
own validated population-based in-house genotyping method to obtain pol sequences. The in-
house genotyping assay used at Tygerberg hospital covers protease (PR) amino acid (aa) 1 to
99 and reverse transcriptase (RT) aa 1 to 262 and has a lower limit of detection of 400 copies/
ml [23] The in-house genotyping assay used at Universitas covers PR aa 1 to 99 and RT aa 1 to
Pre-Treatment HIV-1 Drug Resistance in South Africa
PLOS ONE | DOI:10.1371/journal.pone.0166305 December 1, 2016 3 / 12
240 and has a lower limit of detection of 1000 copies/ml. Finally, the in-house genotyping
assay used at Charlotte Maxeke Johannesburg Academic Hospital covers PR aa 1 to 99 and RT
aa 1 to 418 and has a lower limit of detection of 1000 copies/ml [24, 25].
Sequence analysis
All nucleotide sequences obtained were collated at Charlotte Maxeke Johannesburg Academic
Hospital for analysis. In addition, the Stanford CPR v6.0 (Calibrated Population Resistance)
tool (http://cpr.stanford.edu/cpr.cgi) was used to interpret the level of pre-treatment drug
resistance in the ART naïve population. This tool is based on the 2009 WHO surveillance drug
resistance mutation (SDRM) list [26]. The Stanford HIVdb v7.0.1 tool (http://sierra2.stanford.
edu/sierra/servlet/JSierra) was used to generate predicted resistance profiles. Predicted antire-
troviral drug resistance profiles were categorised as either being susceptible (including poten-
tial low-level resistance), intermediate (including low-level resistance) or high-level resistance.
Subtyping and cross-contamination check
A multiple alignment of the 277 nucleotide sequences with the 2010 subtype reference
sequences from HIV-1 subtypes A to K, and several CRFs (http://hiv-web.lanl.gov), were gen-
erated using Clustal X (version 2.1) (http://www.clustal.org) to determine subtypes as well as
confirm there was no cross-contamination amongst samples. The generated Clustal X align-
ment was used to construct a Neighbor-Joining phylogenetic tree in MEGA 7 (http://www.
megasoftware.net) with the Kimura two-parameter model. The stability of the nodes was
assessed by bootstrap analysis (1000 replicates), and bootstrap values greater than 70% were
considered significant. An additional phylogenetic analysis was conducted for all sequences
with at least one SDRM, to exclude clustering among resistant sequences.
In addition pol subtyping was confirmed by using the Rega HIV subtyping tool v2.0 (http://
bioafrica.net/rega-genotype/html/subtypinghiv.html). Any sequence that was assigned to be a
non-C subtype was also analysed using the NCBI genotyping tool (http://www.ncbi.nlm.nih.
gov/projects/genotyping/) and the jumping profile HMM tool (http://jphmm.gobics.de/
submission_hiv.html) to confirm the subtype.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 6. For all prevalence calculations,
95% confidence intervals were calculated using the modified Wald Method.
Sequence Data
The pol nucleotide sequences were submitted to GenBank using Sequin v13.70 (www.ncbi.
nlm.nih.gov/Sequin) and are available under accession numbers KT892975-KT893251.
Ethics Statement
This study was conducted with ethical clearance by the Research on Human Subjects (Medical)
Committee at the University of the Witwatersrand (Clearance Number M120254). Written
informed consent was obtained from all participants prior to sample collection.
Results
Patient samples were collected between March 2013 and October 2014. Only 320 samples out
of the originally targeted 336 samples were collected. Samples from North West and Western
Cape provinces were underrepresented due to the inability to motivate health care workers
Pre-Treatment HIV-1 Drug Resistance in South Africa
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and/or patients to participate in the survey. For 43 samples, sequences could not be included
due to the inability to obtain a PCR product (n = 31), inadequate completion of the consent
form (n = 5) or participants being younger than 18 years (n = 7). Finally, a total of 277
sequences were available across all nine provinces (Table 1, S1 Fig). The median age of partici-
pants was 34 years (IQR: 29–42) and most participants were female (n = 163, 58.8%). Self-
reported time of diagnosis of HIV-positive status was available for 258 participants at a median
of 44 days (IQR: 23–179) prior to sample collection. Baseline CD4 counts were available for
195 participants and were obtained 16 days (median) before the date of sample collection
(IQR: 8–36). The median baseline CD4 count was 149 cells/mm3 (IQR: 62–249).
The most common pol subtype was HIV-1 subtype C (98.6%). Five sequences belonged to
non-C subtypes. One patient from the Eastern Cape was infected with HIV-1 subtype D; two
patients from Gauteng were infected with HIV-1 subtype B and CRF02_AG, respectively. The
last non-C subtype was detected in KwaZulu-Natal (recombinant between subtype C and A2).
Overall, 25 out of 277 surveyed patients presented with at least one antiretroviral drug resis-
tance mutation. This finding translates into an overall moderate pre-treatment HIV-1 resis-
tance prevalence of 9.0% (95% CI 6.1–13.0%, Table 1). Phylogenetic analysis of these 25
sequences did not reveal any clustering (S2 Fig).NNRTI mutations contributed to the majority
of detected mutations, with 23 patients presenting with at least one NNRTI mutation (8.3%;
95% CI 5.6–12.2%). The most common NNRTI mutation was K103N (n = 16) followed by
Y181C (n = 6) and V106M (n = 3). Seven (2.5%) participants presented with at least one NRTI
mutation. The K65R mutation was the most frequently detected NRTI mutation (n = 4) fol-
lowed by M184V (n = 3). Six individuals (2.2%) were infected with a virus harbouring a com-
bination of at least one NNRTI and one NRTI mutation. Only two participants (0.7%, 95% CI
0.0–2.8%) presented with a PI mutation.
The presence of at least four mutations was observed in four patients. All of these patients
presented with the M184V and/or the K65R mutation. Details about the SDRM detected in the
viruses from these 25 patients are provided in Table 2.
Although no data on the regimen initiation after sample collection was obtained, an
assumption has been made that all patients included in the survey would be initiated on the
standard first-line regimen comprising a combination of tenofovir (TDF), lamivudine/emtrici-
tabine (3TC/FTC) and efavirenz (EFV) as per national guidelines [27]. Results of the sequence
analyses imply that 91.0% (n = 252) of these patients, without any detected antiretroviral drug
resistance, would be initiated on a fully-active triple ART combination. In two additional
patients (0.7%), the detection of a resistance mutation would not affect the activity of the rec-
ommended first-line regimen. Seventeen patients (6.1%) showed resistance against NVP and
EFV prior to ART initiation, which implies that only the NRTI backbone would be active in
these patients. Essentially, these patients are started on a dual regimen. Finally, one patient
(0.4%) would receive TDF monotherapy, whereas for five patients (1.8%) none of the three
drugs in the standard first-line regimen would be active.
Discussion
This pre-treatment antiretroviral drug resistance survey was designed to assess the current
prevalence of HIV-1 drug resistance among South African HIV-infected patients prior to ART
initiation in all nine provinces for the first time. The obtained data is important to verify
whether the currently recommended first-line ART regimens are still adequate to ensure a
good treatment outcome in most HIV-infected patients initiating these regimens. This is the
first survey which includes samples from every province in South Africa, based on the propor-
tion of patients receiving ART in each region.
Pre-Treatment HIV-1 Drug Resistance in South Africa
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Table 2. Detailed antiretroviral drug resistance mutation profiles detected in 25 of the 277 pre-treat-
ment patient samples.
Sample ID # NNRTI
SDRMs
NNRTI SDRMs # NRTI
SDRMs
NRTI SDRMs # PI
SDRMs
PI
SDRMs
GF-EC-A-
013
1 K103N None None
GF-EC-A-
015
1 K103N None None
GF-EC-A-
020
1 Y188L None None
GF-EC-A-
018
1 G190S 1 M184V None
GF-FS-A-
001
1 K103N None None
GF-FS-A-
012
1 L100I None None
GF-FS-A-
007
3 K103N,
V106M,
Y181C
2 K65R, D67N None
GF-GP-A-
049
1 K103N None None
GF-GP-A-
034
1 K103N None None
GF-GP-A-
021
1 Y181C 1 K65R None
GF-KZ-A-
003
1 V106M None None
GF-KZ-A-
035
1 K103N None None
GF-KZ-A-
057
1 K103N None None
GF-KZ-A-
063
1 K103N None None
GF-KZ-A-
089
1 K103N None None
GF-KZ-A-
099
1 K103N None None
GF-KZ-A-
092
2 K103N, Y181C None None
GF-KZ-A-
111
2 K103N, P225H None None
GF-KZ-A-
073
None 1 L210W 1 L90M
GF-KZ-A-
014
3 K103N,
V106M,
M230L
1 K65R None
GF-KZ-A-
051
3 K101E,
Y181C,
G190A
2 K65R, M184V None
GF-LP-A-
011
1 Y181C None None
GF-MP-A-
020
2 K103N, Y181C 6 M41L, Y115F, F116Y,
Q151M, M184V, T215Y
None
GF-MP-A-
009
None None 1 V32I
(Continued )
Pre-Treatment HIV-1 Drug Resistance in South Africa
PLOS ONE | DOI:10.1371/journal.pone.0166305 December 1, 2016 7 / 12
The observed pre-treatment resistance prevalence is classified as a moderate level of 9.0%
(95% CI: 6.1% to 13.0%) according to the WHO classification. This level of pre-treatment drug
resistance was only detected in three South African studies prior to this survey: 9.3% in Lim-
popo [19] and 7.4 [15] and 13.5% [13] in KwaZulu-Natal. However, the increasing prevalence
over the years might be explained by the hypothesis that mature ART programmes can be a
proxy for higher levels of pre-treatment drug resistance [11]. However, other factors, which
were beyond the scope of this study, such as virological failure rates, adherence levels in the
treated population and drug supply continuity, can also affect the levels of pre-treatment drug
resistance. Earlier statistical models predicted that the 5% threshold for TDR would only be
breached 10 years after large-scale ART roll-out or when at least 30% of HIV-infected patients
are on ART [8]. As 2014 marks a decade of large-scale ART roll-out in South Africa and more
than 80% of the HIV-infected South African individuals in need for ART were on treatment
since the end of 2012, the increasing levels of transmitted and/or pre-treatment drug resistance
in the South African population are not unexpected [3]. NNRTI mutations remain the most
commonly observed pre-treatment resistance mutations. Non-TAM mutations such as K65R
and M184V mutations were more commonly observed compared to TAMs, this is a reflection
of the replacement of d4T and AZT by TDF in first-line regimens since 2010 [28]. To our
knowledge it is also the first report on pre-treatment drug resistance that showed the K65R
mutation to be the most commonly observed NRTI mutation.
Based on these findings, only 2.2% of the population initiating ART would likely be started
on monotherapy, or a completely inactive regimen and 6.1% of the study population would be
initiated on dual ART (active TDF and 3TC/FTC). Hamers et al. demonstrated in a large
multi-centre study that pre-treatment drug resistance does have an impact on the outcome of
first-line treatment with an odds ratios for increased virological failure of 2.13 (95% CI: 1.44–
3.14). In addition, patients with pre-treatment drug resistance are more likely to develop
acquired drug resistance as compared to those patients without pre-treatment drug resistance
(OR 2.30, 95% CI: 1.55–3.40) [4].
It can be argued that the patients with multiple antiretroviral drug resistance mutations,
without recorded treatment history, were either not truly drug-naïve or might have been
infected with a multidrug resistant virus. Several studies, especially cluster transmission stud-
ies, have shown that resistance mutations with minimal impact on viral fitness may be trans-
mitted serially without the need for intervening drug pressure [29, 30]. However, the presence
of K65R and/or M184V in each of these individuals might indicate these patients were not
truly ART naïve due to the high fitness cost of both mutations [31–33]. Treatment histories of
these patients with multiple SDRMs were verified and health care workers confirmed these
patients did not disclose and prior ART exposure. The resistance profile of these patients is of
concern as the likelihood of virological suppression on standard first-line regimens is limited.
However, health care professionals would not be able to become aware of these mutations in
routine care since HIV-1 drug resistance testing is currently not recommended prior to ART
initiation.
Table 2. (Continued)
Sample ID # NNRTI
SDRMs
NNRTI SDRMs # NRTI
SDRMs
NRTI SDRMs # PI
SDRMs
PI
SDRMs
GF-NW-A-
003
1 K103N None None
Samples highlighted in grey might not represent true ART naïve patients.
doi:10.1371/journal.pone.0166305.t002
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Despite the adequate sample size and PPSS study design, the study had some limitations.
Firstly, the enrolment of patients into the study was largely dependent on the willingness of cli-
nicians and nurses to obtain consent from patients, complete study questionnaires and collect
specimens, as there was no provision of study-specific staff to assist in the survey. These activi-
ties place a burden on clinics that are often already under-resourced and thus demonstrate the
difficulties in conducting such surveys and the vast costs associated with their completion.
These challenges resulted in a relatively long period to complete sample collection. Overall
82% of the planned sample size was collected and analysed. But there was under-sampling
from North West, and Western Cape provinces.
Secondly, patients were not systematically sampled at the clinic level. This approach might
have introduced a selection bias as sample selection was dependent on willingness of health
care workers and patients to comply with the added burden of the study. However, we don’t
believe that it is possible for clinicians to choose treatment naïve patients based upon demo-
graphic or clinical characteristics that would bias the proportion of SDRM.
Thirdly, data quality was dependant on the completeness and accuracy of the question-
naires. Moreover, no specific information regarding exposure to Prevention-of-Mother-to-
Child-Transmission prophylaxis was obtained and may have potentially overestimated the
level of pre-treatment drug resistance caused by the use of PMTCT regimens, especially since
most patients were female. In addition, information regarding prior ART exposure could only
be verified based on verbal confirmation from participants or notes in the patient’s hospital
files, which might have led to the inclusion of patients with undisclosed ART exposure. Finally,
resistance mutations were detected by population-based Sanger sequencing which might
underestimate the prevalence of minority drug resistance mutations, due to sensitivity limita-
tions of this approach, especially in patients who have been chronically infected before ART
initiation. This study might have underestimated the level of pre-treatment resistance; since it
is likely the sample included a substantial proportion of chronically infected patients, indicated
by the low median CD4 count of 149 cells/mm3. It is known that TDR mutations can revert
back to wild type in the bulk viral population, especially without the presence of drug pressure.
It is therefore possible that archived mutations were missed in this analysis. However, these
limitations are largely overcome by the large sample size of the study and the fact that samples
were collected from all provinces, proportional to the number of patients on ART.
Overall, this study has shown that the level of antiretroviral drug resistance in ART-naïve
South Africans is on the rise. Regional analyses indicate that there might be a difference in the
level of drug resistance between provinces, although this trend needs to be confirmed by
repeating surveys in each province with larger sample sizes. Despite the availability of routine
viral load testing in the public sector, there is often a delayed response to changing manage-
ment based on virological failure which could have contributed to the transmission of drug
resistance [34]. These findings strongly suggest a renewed focus on first-line treatment success
(the last 90% of the UNAIDS 90-90-90 strategy) with regular regional surveillance of pre-treat-
ment drug resistance levels in all regions of the country.
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